Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Merck
McKesson
Dow
Boehringer Ingelheim

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

PRISTIQ Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Pristiq, and what generic alternatives are available?

Pristiq is a drug marketed by Pf Prism Cv and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-eight patent family members in thirty-two countries.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Drug patent expirations by year for PRISTIQ
Drug Prices for PRISTIQ

See drug prices for PRISTIQ

Drug Sales Revenue Trends for PRISTIQ

See drug sales revenues for PRISTIQ

Recent Clinical Trials for PRISTIQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Luye Pharma Group Ltd.Phase 1
Seoul National University Bundang HospitalPhase 4
Seoul National University HospitalPhase 4

See all PRISTIQ clinical trials

Recent Litigation for PRISTIQ

Identify potential future generic entrants

District Court Litigation
Case NameDate
Pfizer Inc. v. Apotex Inc.2012-06-22
Pfizer Inc. v. Mylan Pharmaceuticals Inc.2012-06-22
Pfizer Inc. v. Zydus Pharmaceuticals USA Inc.2012-06-22

See all PRISTIQ litigation

US Patents and Regulatory Information for PRISTIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for PRISTIQ
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe   Start Trial
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe   Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Moodys
McKinsey
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.